Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06626919
Recruiting Phase 1

Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

NCT06626919 · tracked via the Priya Life Science USA tracker
Sponsor
Kite, A Gilead Company
Phase
Phase 1
Started
2025-04-30
Last updated
2026-10-22

Condition(s) studied

Muscular DiseasesNeuromuscular ManifestationsAutoimmuneAutoimmune DiseasesAutoimmune Diseases of the Nervous SystemMyasthenia GravisMuscle Weakness

Investigational drug(s) / intervention(s)

anito-cel →Cyclophosphamide →Fludarabine →

anito-cel: Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain

Cyclophosphamide: Administered intravenously

Fludarabine: Administered intravenously

Study summary

The goal of this clinical study is to learn more about the study drug Anitocabtagene autoleucel (anito-cel), and its safety, tolerability, dosing, and preliminary effectiveness in participants with generalized myasthenia gravis (GMG). Anito-cel is a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy.

The primary objective of this study is to assess the safety profile, including any dose-limiting toxicity (DLT) and identification of a maximum tolerated dose (MTD) (if applicable), to support selection of the recommended Phase 2 dose (RP2D) of anito-cel when administered to participants with GMG.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * Individuals must be 18 years of age or older * Must have Myasthenia Gravis Foundation of America (MGFA) clinical classification Grades 2-4A at time of screening * Participant must have clinically active disease and requiring ongoing therapy for Generalized Myasthenia Gravis (GMG) * MG-ADL score ≥ 6 and QMG score ≥ 10 at screening * GMG specific autoantibodies must be above the reference laboratory upper limit of normal (ULN) Key Exclusion Criteria: * Individual is pregnant or breastfeeding * Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion * Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager * Previous thymectomy within 6 months of screening * Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcome measure(s)

  • Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAE) — First dose date up to 24 months
  • Percentage of Participants Experiencing Dose-Limiting Toxicities (DLT) — Up to 28 days following anito-cel infusion
  • Maximum Tolerated Dose (MTD) of Anito-cel — First dose up to 30 days (Up to 24 months)
  • Percentage of Participants With Laboratory Abnormalities — First dose date up to 24 months
  • Recommended Phase 2 Dose (RP2D) of Anito-cel — Up to 24 months

Trial sites (14)

FacilityCityRegionStatus
Ronald Reagan UCLA Medical Center Los Angeles California Recruiting
UC Irvine Medical Center Orange California Recruiting
Stanford Blood and Marrow Transplant Palo Alto California Recruiting
Moffitt Cancer Center Tampa Florida Recruiting
University of South Florida - Carol and Frank Morsani Center for Advanced Healthcare Tampa Florida Recruiting
Karmanos Cancer Institute Detroit Michigan Recruiting
University of Minnesota Delaware Clinical Research Unit Minneapolis Minnesota Recruiting
Mayo Clinic Rochester Minnesota Recruiting
Columbia University Irving Medical Center New York New York Recruiting
The Ohio State University Wexner Medical Center Columbus Ohio Recruiting
Oregon Health & Science University Portland Oregon Recruiting
Lewis Katz School of Medicine at Temple University Philadelphia Pennsylvania Recruiting
UT Southwestern Medical Center Dallas Texas Recruiting
Houston Methodist Hospital Houston Texas Recruiting

More Kite, A Gilead Company trials in the USA

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma Active, not recruiting
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment Recruiting
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) Active, not recruiting
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases Enrolling by invitation
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma Active, not recruiting

Other trials for the same condition

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis Recruiting
Vitaccess Real MG Registry Recruiting
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment Recruiting
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT) Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06626919 on ClinicalTrials.gov ↗ ← All trials in the USA